HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
2276studies shown
Showing 997-1,008 of 2,276
Drug study icon
CompletedACTRN12617001258347

A Single-Center, Pharmacokinetic (PK) Study to Assess the PK Profile of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS2)

Official study title

A Single-Center, Open-Label Pharmacokinetic (PK) Study in male smokers to Assess the PK Profile of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS2)

This study has finished and is no longer accepting participants.

In Australia
AddictionInterventional studyAges 18+
Countries
Australia
Sponsor
Chrono Therapeutics Australia PTY LTD
Drug study icon
CompletedACTRN12616000824460

A Single-Center, Two-Period, Cross Over, Pharmacokinetic Study to Assess the Relative Bioavailability of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS1) versus NicoDerm (Registered Trademark) CQ (Registered Trademark) Patch

Official study title

A Single-Center, Randomized, Open-Label, Two-Period, Cross Over, Pharmacokinetic Study to Assess the Relative Bioavailability of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS1) versus NicoDerm (Registered Trademark) CQ (Registered Trademark) Patch in Smokers

This study has finished and is no longer accepting participants.

In Australia
AddictionInterventional studyAges 18+
Countries
Australia
Sponsor
Chrono Therapeutics Australia PTY LTD
Behavioral study icon
CompletedACTRN12615000165583

A stepped wedge cluster controlled study of a healthy lifestyle intervention for people attending residential substance abuse treatment

Official study title

A stepped wedge cluster randomised controlled trial of a healthy lifestyle intervention for people attending residential substance abuse treatment

This study has finished and is no longer accepting participants.

In Australia
Mental healthInterventional studyAges 18+
Countries
Australia
Sponsor
University of Wollongong
Behavioral study icon
WithdrawnACTRN12620000053921

A text-message based, brief intervention after hospitalisation for Suicide prevention, a Suicide prevention or Suicide prevention.

Official study title

An optimisation trial of an SMS-based, brief intervention after hospitalisation for self-harm, a suicide attempt, or suicidal ideation, targeting proximal risk factors for self-harm and suicide.

This study was withdrawn before enrollment.

In Australia
SuicidalityInterventional studyAges 16–65
Countries
Australia
Sponsor
University of New South Wales
Drug study icon
CompletedNCT05455684

Aticaprant for depression

What is this study about?

This study evaluated the safety and effectiveness of Aticaprant for people with depression.

This study has finished and is no longer accepting participants.

In Australia
DepressionMedication studyAges 18–74
Countries
Australia, United States, Belgium, + 10 others
Sponsor
Janssen Research & Development, LLC
Drug study icon
CompletedNCT03345342

Paliperidone Palmitate 6-Month Formulation

Official study title

A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

This study has finished and is no longer accepting participants.

In Australia
SchizophreniaMedication studyAges 18–70
Countries
Australia, United States, France, + 18 others
Sponsor
Janssen Research & Development, LLC
Behavioral study icon
CompletedACTRN12621001097831

Psilocybin-assisted psychotherapy for treatment-resistant depression

What is this study about?

This study evaluated the effectiveness of psychotherapy for people with depression.

This study has finished and is no longer accepting participants.

In Australia
DepressionInterventional studyAges 18–65
Countries
Australia
Sponsor
Swinburne University of Technology
Drug study icon
TerminatedNCT00256997

Risperidone Long-Acting Injection Versus Oral Antipsychotics for schizophrenia

Official study title

Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting

This study ended early.

In Australia
SchizophreniaMedication studyAges 18–65
Countries
Australia, Canada, United Kingdom, + 1 other
Sponsor
Janssen-Ortho Inc., Canada
Drug study icon
CompletedACTRN12621001365853

RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers

Official study title

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers

This study has finished and is no longer accepting participants.

In Australia
AnxietyInterventional studyAges 18–55
Countries
Australia
Sponsor
Receptor Life Sciences Australia Pty Ltd

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.